Technology company
Medigus Ltd. (NASDAQ: MDGS, Forum) released details on a move by its affiliate,
Gix Internet (TASE: GIX), a global marketing technology solutions company for online performance-based-marketing, announced that its subsidiary,
Gix Media signed a definitive agreement for the purchase of 70% at
Cortex Group, an innovative media-tech company that has developed expertise in turning original content into a profit center through user traffic acquisition.
The acquisition of 70% of Cortex's shares by Gix Media will be made for approximately $ 11 million (USD), with the final
amount to be determined on the closing date of the transaction. According to Gix Internet’s financial reports for the first six months of 2021, its revenues amounted to roughly $ 16.4 million (USD).
For the full story, click
here.
Engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, Medigus announced last week that
Polyrizon Ltd., a private company that it owns a significant stake in had presented pre-clinical data that showed its distinct platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and could also potentially treat additional cold viruses.
The Health Care seed-stage company develops novel biological-gels and in
a media release for investors, Medigus stated that the data that Polyrizon shared from its cell-culture study confirmed that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza virus H1N1.
Polyrizon’s new product candidate protects the nasal cavity and the respiratory tract. In its H1N1 studies, product candidates demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibit cells death.
It was also pointed out that use of the Capture and Contain platform technology would help provide a boost in Polyrizon’s product line extended against flu and cold viruses along with a variety of different respiratory viruses.
For more details on the company, visit
medigus.com.
FULL DISCLOSURE: Medigus Ltd. Is a client of Stockhouse Publishing.